Recent estimates indicate that tuberculosis (TB) is the leading cause of death worldwide,
alongside the human immunodeficiency virus (HIV) infection. The current treatment is …

Tuberculosis (TB) is an intracellular infectious disease caused by the airborne bacterium,
Mycobacterium tuberculosis. Despite considerable research efforts, the treatment of TB …

Background Polylactides (PLA) and poly lactide-co-glycolides (PLGA) undoubtedly are
among the major drivers in the pharmaceutical market. Their relevance in pharmaceutics …

Tuberculosis is the leading cause of death from a single infectious pathogen worldwide.
Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing …

Tuberculosis (TB) is a major global health burden. The emergence of the human
immunodeficiency virus (HIV) epidemic and drug resistance has complicated global TB …

Pulmonary delivery of nanocarriers for novel antimycobacterial compounds is challenging
because the aerodynamic properties of nanomaterials are sub-optimal for such purposes …

Pharmacotherapy of tuberculosis is potentially more efficient when delivered by the inhaled
route than by the current oral and/or parenteral routes due to the higher concentration of …

Delivery of drugs to the lungs via dry powder inhaler (DPI) is a promising approach for the
treatment of both local pulmonary conditions and systemic diseases. Though DPIs are …

The ability of niosomes to entrap both hydrophilic (D-Cycloserine) and lipophilic
(Ethionamide) drugs was utilized to make an effective formulation for combating drug …

Drug-resistant tuberculosis (DR-TB) is an emerging health problem, challenging the
effective control of global TB. Current treatment of DR-TB includes administration of multiple …